State Street Corp Caladrius Biosciences, Inc. Transaction History

State Street Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$0.63 - $1.03 $3,969 - $6,489	6,300 Added 3.01%	215,261 $155,000
Q4 2021 Feb 14, 2022	SELL	$0.83 - $1.22 $7,138 - $10,492	-8,600 Reduced 3.95%	208,961 $176,000
Q3 2021 Nov 15, 2021	BUY	$1.15 - $1.57 $11,730 - $16,014	10,200 Added 4.92%	217,561 $265,000
Q2 2021 Aug 16, 2021	BUY	$1.4 - $1.9 $290,305 - $393,985	207,361 New	207,361 $334,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.